See our current products

Get to know our current offerings to see what we’re doing right now to address challenges in transplant.

current products
CURRENT PRODUCTS

Our focus (in market)

At Veloxis, a core focus is expanding access to and awareness of our currently marketed products and technologies.

ENVARSUS XR® (tacrolimus extended-release tablets)

ENVARSUS XR is a once-daily, extended-release tacrolimus formulation created with proprietary MeltDose® technology.1

ENVARSUS XR is indicated for the prophylaxis of organ rejection in de novo kidney transplant patients in combination with other immunosuppressants.2

ENVARSUS XR is also indicated for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants.2

Please see Important Safety Information below and full Prescribing Information (PDF), including Boxed Warning and Medication Guide.

Visit ENVARSUSXR.com
References
1. Bunnapradist S, Rostaing L, Alloway RR, et al. LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups. Transpl Int. 2016;29(5):603-611. 2. ENVARSUS XR [package insert]. Cary, NC: Veloxis Pharmaceuticals, Inc.; 2020.

We’re committed to supporting patients on treatment

Veloxis works hard to ensure patient access and financial support for kidney transplant patients. Learn more about the services we offer.

See how we can help